Shares of Israeli drug developer Intec Pharma Ltd. ended their stock market debut unchanged Tuesday while the broader markets declined.
Intec raised more than $30 million in its initial public offering, selling 5 million shares at $6 per share. It plans to use the money raised to fund a clinical drug trial for its Parkinson's disease treatment that it is developing.
The company's shares are trading on the Nasdaq stock market under the ticker symbol "NTEC."
They traded in a range between $5.58 and $6.02 Tuesday before ending at $6.
This content appears as provided to The Globe by the originating wire service. It has not been edited by Globe staff.